Business
Catalyst Pharmaceuticals sells specialty medicines including Firdapse, Agamree, and Fycompa.
Catalyst grew revenue and earnings, but FCF fell from a very high margin.
The read at a glance✓ Audited against SEC data
- Business mix — Firdapse, Agamree, FycompaOK
- Revenue — $588.99M, +19.8%OK
- Net income — $214.33M, +30.8%OK
- FCF — $208.61M, -12.8%Watch
- FCF margin — 35.4%, -1323 bpsWatch
- Altman/Beneish/EQ — Safe Z; clean M/EQOK
- Insiders — 0 purchases / 9 salesWatch
Where the revenue comes from
Fiscal 2025, as CATALYST PHARMACEUTICALS, INC. reports it. History and quarterly detail are in the app.
- Product Revenue Net$588.8M
- Firdapse$358.4M
- Agamree$117.1M
- Fycompa$113.3M
- License And Other Revenue$182K
Leadership changes
From CATALYST PHARMACEUTICALS, INC.'s own filings, the day they're filed.
- Molly Harper · Directors · appointment
- Charles B. O'Keeffe · Directors · appointment
- Donald A. Denkhaus · Directors · appointment
Latest filings
- 8-K · Company announcement2026-07-16
- 8-K · Company announcement2026-07-08
- 8-K · Company announcement2026-06-30
- 8-K · Company announcement2026-06-23
- 8-K · Company announcement2026-05-11
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CATALYST PHARMACEUTICALS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.